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Abstract
Background:  Glioblastomas (GBM) are typically comprised of morphologically diverse cells.
Despite current advances in therapy, including surgical resection followed by radiation and
chemotherapy, the prognosis for patients with GBM remains poor. Unfortunately, most patients
die within 2 years of diagnosis of their disease. Molecular abnormalities vary among individual
patients and also within each tumor. Indeed, one of the distinguishing features of GBM is its marked
genetic heterogeneity. Due to the brain location of the tumor, the potential target inhibition for
anticancer therapy must exhibit a manageable neurotoxicity profile in the concentration range in
which the compounds show anti-proliferative activity.
Kinesin KIF11 inhibition by small molecules such as Monastrol or Ispinesib is currently under
investigation in the field of malignant tumors. In the current study we have assessed the relevance
of the anti-mitotic Kinesin-like protein KIF11 in human GBM cell-lines.
Results: In this study the target was validated using a set of well characterised and potentially
specific small molecule inhibitors of KIF11: an ispinesib analog, Monastrol, a Merck compound and
3 simplified derivatives of the Merck compound. Following an in silico selection, those compounds
predicted to bear a favorable BBB permeation profile were assessed for their phenotypic effect on
cell lines derived both from primary (U87MG) as well as treated (DBTRG-05-MG) glioblastomas.
For some compounds, these data could be compared to their effect on normal human astrocytes,
as well as their neurotoxicity on primary rat cortical neurons. The ispinesib analogue 1 showed an
anti-proliferative effect on GBM cell lines by blocking them in the G2/M phase in a concentration
range which was shown to be harmless to primary rat cortical neurons. Furthermore, ispinesib
analog increased caspase 3/7-induced apoptosis in U87MG cells.
Conclusion: In the area of cell cycle inhibition, KIF11 is critical for proper spindle assembly and
represents an attractive anticancer target. Our results suggest that KIF11 inhibitors, when able to
permeate the blood-brain-barrier, could represent an interesting class of anticancer drugs with low
neurotoxic effects in the treatment of brain tumors.
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Background
Malignant gliomas, the most common subtype of primary
brain tumors, are aggressive, highly invasive, and neuro-
logically destructive tumors considered being amongst the
deadliest forms of human cancers. The most widely used
scheme for classification and grading of gliomas is that of
the World Health Organization (WHO). Gliomas are
graded on a scale from I to IV according to their degree of
malignancy; the most aggressive being grade IV or Gliob-
lastoma Multiforme (GBM).
The current study focused on GBM as it is considered the
most common and most dramatic primary brain tumor in
adults, with highest incidence in the elderly. Median sur-
vival for patients affected with GBM is only 9 to 15
months, and the majority of patients die within 2 years.
The only -albeit moderately – successful currently used
standard of care consists of a combination of surgery,
chemo- and radiotherapy. Following surgery, patients are
typically subjected to radiotherapy in combination with
Temozolomide, an orally available DNA alkylating agent.
Subsequently patients are further kept under Temozolo-
mide treatment. Although there is no real difference in
clinical benefit between patients with primary (de novo)
or secondary (originally derived from low grade gliomas)
GBMs [1], an impressive improvement of Temozolomide
efficacy has been shown in patients expressing a methyl-
ated promotor of the methyl-guanidine-methyl trans-
ferase (MGMT) gene. The latter encodes for a DNA repair
enzyme and is deemed responsible for a decreased Temo-
zolomide DNA alkylating efficacy [2]. This limitation,
together with the inherent, mechanism of action-linked
toxicity of Temozolide also implies that the identification
of better, molecular targeted therapies for the treatment of
GBM remains.
In order to successfully eradicate GBM, a number of obsta-
cles due to the location (the brain) and the nature (heter-
ogeneous, infiltrating) of the tumor have to be overcome.
GBMs do not only grow locally but infiltrate neighboring
brain tissue through white matter tracts, perivascular, and
periventricular spaces, and invading cells are often found
centimeters away from the primary tumor mass [3]. The
tumor's invasive nature is one of the cardinal features of
malignant gliomas. This results in the inability of surgery
to cure patients even when lesions arise in areas in which
wide surgical resection would be possible. Chemotherapy
should therefore be aimed at also affecting those tumor
cells which are located in unresectable tumor areas. Since
the blood-brain-barrier (BBB) could be expected to be
intact in these areas, disease-modifying pharmacological
intervention requires BBB-penetrating compounds.
Predicting central nervous system (CNS) partitioning
remains a major challenge in drug design and needs to
take a series of molecular properties into account already
at the compound library design stage. In vivo experimental
determination of blood-brain partitioning is difficult. It is
time-consuming, expensive, and not suitable to screen
large collections of chemicals or to assess the permeation
of compounds at the beginning of the discovery process
[4]. In vitro methods (passive artificial membrane perme-
ability models, cellular monolayer models) are useful,
although predictivity remains limited as the models can-
not completely mimic the complexity of a dynamic in vivo
system. Therefore computational (in silico) models have
been developed in order to allow screening of large collec-
tions of compounds and to understand structure-activity
relationships. From a target point of view, successful GBM
treatment is hampered by the tumors cellular heterogene-
ity which features include proliferative, hypoxic and inva-
sive cells.
Within the current study we decided to focus on the anal-
ysis of targets which affect GBM proliferation since in gen-
eral anticancer drugs that perturb mitosis have been
shown to play an important role in the therapy of malig-
nant diseases. Targeted therapies under current investiga-
tion that are known to affect the cell cycle could be
subdivided in three categories:
- Kinase inhibitors (mostly Cyclin-Dependent Kinases)
- DNA modifying agents (Alkylating agents, Topoisomer-
ase inhibitors)
- Tubulin/microtubules modulators
Kinase inhibitors of the ATP-competitive sort are at risk of
potential toxicity in relation to their potential lack of
selectivity within the kinome. DNA modifying agents are
known for their toxicity and/or drug resistance issues.
Some tubulin/microtubule modulators show a significant
effect on mitosis-independent cytoskeletal functions [5,6]
such as maintenance of organelles, cell shape and intrac-
ellular transport phenomena. Since, especially neuronal
processes highly depend on an intact cytoskeleton; the
tubulin/microtubule modulator of choice should be such
that only tumor mitosis is affected, leaving the mitosis-
independent (and thus neuronal) functions untouched.
Therefore, the potential value of kinesin inhibitors has
been assessed. Kinesins are eukaryotic microtubule-asso-
ciated motor proteins, which convert chemical energy
released from nucleoside triphosphates (preferentially
from ATP) into mechanical energy. There are over forty
kinesins found in humans which all have a similar motor
domain that uses ATP to perform its power stroke [7-9].
The difference between them is mostly determined by the
nature of the adapters that attach the motor to the object
that needs to be moved [10]. Kinesins can be classifiedBMC Cancer 2009, 9:196 http://www.biomedcentral.com/1471-2407/9/196
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according to function as either transport or mitotic kines-
ins. Transport kinesins play amongst others an essential
role in the cytosolic movement and localization of synap-
tic vesicles in neurons and in physiological axonal trans-
port processes [11].
Mitotic kinesins are involved in mitotic spindle assembly,
maintenance and elongation, chromosome alignment
and segregation, and microtubule depolymerisation,
among other functions during cell division.
In this panorama, only the identification of highly specific
and preferentially allosteric mitotic kinesin inhibitors
which have the capacity to penetrate the BBB represent
according to us a promising class of novel therapeutics for
GBM.
Results
Descriptors calculation and BBB permeation prediction. 
Compound 1 is active and predicted to be BBB permeable
Kinesin inhibitors (compounds 1–6,) were analyzed in
VolSurf for their CNS-partitioning properties, producing
94 molecular descriptors (grid spacing 0.5 Å) using three
probes: a water probe (OH2) for hydrophilicity, a hydro-
phobic (DRY) probe computing the hydrophobic energy
to be balanced with the hydrophilic energy computed by
the OH2 probe, and a carbonyl oxygen probe (O) repre-
senting the hydrogen bond potential of the compounds.
The DRY probe is a specific probe to compute hydropho-
bicity that can be estimated by means of the computation
of three terms: the Lennard-Jones potential (that includes
stacking, induction, and dispersion interactions with a
maximum around -2.0 kcal/mol), the entropic (about -
0.8 kcal/mol) and hydrogen-bonding contributions. The
prediction of these seven compounds onto the global BBB
model implemented in VolSurf resulted as shown in Fig-
ure 1.
In spite of classically unfavorable BBB characteristics
(high molecular weight and high number of rotatable
bonds) compound 1, with a molecular weight of 583 and
10 rotatable bonds, was predicted by the Volsurf BBB glo-
bal model to be in the "medium/undefinied" area of the
graph. Since the Volsurf data were not decisive, a cross-val-
idation using Cerius2 has been performed. This software
predicted compound 1 to be BBB permeable. This second
prediction is supported by the coumpound s detailed
physico-chemical profile (Table 1), which shows a low
number of hydrogen bond donor and acceptor functions,
optimal lipophilicity and low polar surface area.
In this sense, the results from VolSurf were confirmed and
compound 1 (in its neutral form) was predicted to have a
higher probability of being BBB permeable (bold, Table
1) than compound 2 (underlined, Table 1) in its neutral
form. Compound 3 was flagged (italic, Table 1) in the
cross-validation method despite being a non-charged
molecule at physiological pH, probably due to its unfavo-
rable calculated physico-chemical properties (low AlogP,
higher PSA).
All 'Merck fragments' (4, 5 and 6), were predicted to be
CNS-penetrant according to both in silico models consid-
ered. Their potential for BBB penetrating capacity is also
endorsed by their physico-chemical properties: they have
a low molecular weight, a low number of rotatable bonds
and few or no hydrogen bond donor/acceptor(s). The lat-
ter feature results in a reduction of the polar surface area
and very acceptable values of lipophilicity when expressed
as ALogP (Table 1).
Taken together, the physico-chemical features of 1 and the
prediction onto the BBB in silico models give higher
chances for this compound to reach the brain; a calculated
high lipophilicity together with a small polar surface area
should increase the molecule's ability to cross the blood-
brain barrier. It is of note that the combination of
Projection of the seven kinesin inhibitors onto the Volsurf  global BBB model Figure 1
Projection of the seven kinesin inhibitors onto the 
Volsurf global BBB model. The blue circles at the left of 
the red line are those compounds belonging to the model 
and experimentally determined as BBB negative (non perme-
able) and the red circles above the blue line are those com-
pounds which have been experimentally determined as BBB 
positive (permeable). Compounds projected within the area 
included between the red and the blue line (the uncertainty 
area) show a certain level of uncertainty and their BBB pene-
trating capacity should be cross validated using an additional 
model system.BMC Cancer 2009, 9:196 http://www.biomedcentral.com/1471-2407/9/196
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lipophilicity (here expressed as ALogP) and hydrogen-
bonding (PSA) descriptors is a feature of many state-of-
the-arts in silico BBB models [12].
Ispinesib analogue 1 is anti-proliferative and significantly 
more effective than Monastrol (3) and Merk fragments (4 
and 5)
The first stage of a study on the possibility of selectively
inhibiting KIF11 in GBM with a brain entrant small mol-
ecule was to synthesize known inhibitors and to test
against GBM cells.
Compounds 1, 3, 4, 5 and 6, which bear a positive in silico
profile, were first tested for their antiproliferative effect on
GBM cell-lines in an MTT proliferation assay: U87MG and
DBTRG-05-MG cells were treated for 72 hours with the
KIF11 kinesin inhibitors at concentrations varying from
10 nM to 200 mM, 24 h after seeding (compound 1 from
10 nM to 20 mM, compound 3, 4, 5 and 6 from 10 nM to
200 mM). In these experiments, the media containing the
compound was not changed during the whole incubation
period. Doxorubicin, a well known anti-proliferative
compound, was used as positive control (data not
shown). The anti-proliferative activity was calculated as
percentage of the remaining viable cells after treatment
versus untreated cells. The results of these experiments are
shown in figures 2 and 3. Ispinesib analog 1, Monastrol 3
and Merck fragments 4 and 5 induced a significant reduc-
tion in GBM cell proliferation, while compound 6 didn t
seem active, even at the highest concentrations. However,
Monastrol 3 – analogously to what reported in the litera-
ture [13]- and both the Merck fragments (4-5) proved
much less potent (Monastrol 3  IG50 = 114 3M against
U87MG and 117 3M against DBTRG-05-MG, Merck frag-
ment 4 IG50 = 52 3M against U87MG and 36 3M against
DBTRG-05-MG and Merck fragment 5  IG50  = 14 3M
against U87MG and 11 3M against DBTRG-05-MG) than
the Ispinesib analog (1) which showed an IG50 = 367 nM
against U87MG and 712 nM against DBTRG-05-MG.
Ispinesib analogue 1 induces G2/M cell cycle arrest and 
induces apoptosis
As it is known that KIF11 inhibitors induce a collapse of
bipolar spindle with a consequent formation of a monop-
olar spindle resulting in a block of the cell-cycle [14], we
assessed whether the Ispinesib analog 1 affects the cell-
cycle in GBM cell lines. Following 24 hours of serum dep-
rivation in order to reach cell cycle synchronization,
U87MG and DBTRG-05-MG cells were treated with
Ispinesib analog compound 1 at a fixed concentration of
1  mM for 24 hours. Nocodazole (a tubulin inhibitor
known to block the cell-cycle in the G2/M phase) was
used as a positive control. After incubation, the cells were
fixed and stained with propidium iodide. Flow cytometry
analysis of the cells showed that the Ispinesib analog 1
had a potent effect on the cell-cycle. The treated cells (Fig-
ures 4b and 5b) demonstrated a significant increase in the
amount of 4N DNA (G2/M = 61%) and subsequent
decrease in 2N DNA (G1 = 22%) in comparison to the
untreated cells (Figures 4a and 5a) (G2/M = 46% and G1
= 40%). These data are similar to those observed with
Nocodazole (Figures 4c and 5c), and thus suggest that
compound 1 is able to induce a block in the G2/M phase
in both cell-lines as a result of a failure in cytokinesis.
The data obtained indicated that compound 1 induces a
mitotic arrest in glioma cells, supporting its role as a
potential anticancer target.
In most cases, mitotic arrest induces apoptosis through
mitochondrial membrane depolymerisation and caspase
3 activation. As kinesin inhibitors are known to increase
caspase dependent apoptosis in a variety of tumor cell
lines [5-16] the ability of compound 1 to induce apopto-
Table 1: Lipinski profile and BBB models prediction of the seven compounds
Compound number MW RBT HBAcc HBDon PSA AlogP Cerius2 prediction VolSurf prediction
1 583 10 5 1 56 5.6 High penetrant (1) Medium/Undefined
2 355 5 3 3 53 2.9 Medium penetrant (2) Low permeant
32 9 2 5 4 3 7 3 1 . 7 Low penetrant (3) High permeant
42 5 5 2 2 1 2 6 4 . 4 Very penetrant (0) High permeant
52 5 5 2 2 1 2 6 4 . 4 Very penetrant (0) High permeant
62 9 4 4 3 0 4 1 2 . 9 High penetrant (1) High permeant
Lipinski profile of the seven studied compounds and their predictions onto the BBB models of Cerius2 and Volsurf, based on their physico-chemical 
descriptors. Legend: MW = Molecular Weight; HBA = Hydrogen Bond Acceptors; HBD = Hydrogen Bond Donor; PSA = Polar Surface Area; AlogP 
= Negative logarithm of the octanol/water partition of the molecule.BMC Cancer 2009, 9:196 http://www.biomedcentral.com/1471-2407/9/196
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Antiproliferative effect of KIF11 inhibitors on U87MG GBM cells Figure 2
Antiproliferative effect of KIF11 inhibitors on U87MG GBM cells. All the panels a), b), c), d) and e) represented the 
concentration-response curve of the compounds 1, 3, 4, 5 and 6 respectively. The cells were treated for 72 hours with 
increasing concentrations of the KIF11 inhibitor compounds 1, 3, 4, 5 and 6. After the treatment the cell viability/proliferation 
were measured using the MTT assay. The analysis of the data was performed using XLfit4 software. The normalization is made 
taking the control as 100%. Each experiment was repeated three times at least in duplicate. Only compound 1 showed an IG50 
in a sub-micromolar range.
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Antiproliferative effect of KIF11 inhibitors on DBTRG-05-MG GBM cells Figure 3
Antiproliferative effect of KIF11 inhibitors on DBTRG-05-MG GBM cells. All the panels a), b), c), d) and e) repre-
sented the concentration-response curve of the compounds 1, 3, 4, 5 and 6 respectively. The cells were treated for 72 hours 
with increasing concentrations of the KIF11 inhibitor compounds 1, 3, 4, 5 and 6. After the treatment the cell viability/prolifer-
ation were measured using the MTT assay. The analysis of the data was performed using XLfit4 software. The normalization is 
made taking the control as 100%. Each experiment was repeated three times at least in duplicate. Only compound 1 showed an 
IG50 in a sub-micromolar range.
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Cell cycle profile on U87MG GBM cells Figure 4
Cell cycle profile on U87MG GBM cells. Effect of the compound 1 on the cell cycle of U87MG cells. The cells were un-
treated (figure 4a), treated with 1 mM of the Ispinesib analog compound 1 for 24 hours (Figure 4b) after 24 hours starvation. 
Nocodazole treatment was used as positive control (Figure 4c). Following incubation, the DNA of the cells was stained with 
propidium iodide and its content was analyzed by flow cytometry. Compound 1 induced a block of the cell cycle in G2/M 
phase. M1 was marker 1 and it represented G0/G1 phase; M2 was marker 2 and it represented the S phase; M3 was marker 3 
and it represented G2/M phase.
a)
b)
c)BMC Cancer 2009, 9:196 http://www.biomedcentral.com/1471-2407/9/196
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Cell cycle profile on DBTRG-05-MG GBM cells Figure 5
Cell cycle profile on DBTRG-05-MG GBM cells. Effect of the compound 1 on the cell cycle of DBTRG-05-MG cells. The 
cells were un-treated (Figure 5a), treated with 1 mM of the Ispinesib analog compound 1 for 24 hours (Figure 5b) after 24 h 
starvation. Nocodazole treatment was used as positive control (Figure 5c). Following incubation, the DNA of the cells was 
stained with propidium iodide and its content was analyzed by flow cytometry. Compound 1 induced a block of the cell cycle in 
G2/M phase. M1 (marker 1) represented G0/G1 phase; M2 (marker 2) represented the S phase; M3 (marker 3) represented 
G2/M phase.
a)
b)
c)BMC Cancer 2009, 9:196 http://www.biomedcentral.com/1471-2407/9/196
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sis in GBM cell lines was investigated. Caspase-3 activa-
tion level was thus assessed after 24 hours of treatment
with compound 1 at various concentrations (from 10 nM
to 30 mM) against U87MG cells (Figure 6). Ispinesib ana-
log 1 induced caspase 3 activation starting from the con-
centration of 300 nM up to a maximal 2-fold increase of
activity at 1 mM. The observed decrease at much higher
concentration of 1 (10 and 30 mM) could, in our opinion,
be ascribed to a toxic effect. From these results we could
conclude that this compound is a strong inducer of cas-
pase 3-mediated apoptosis in U87MG cells.
Ispinesib analogue 1 does not affect cell viability of human 
normal astrocytes and rat cortical neurons
The potential for neurotoxic side effects of the Ispinesib
analog 1 was assessed by measuring its effect on normal
human astrocytes viability. The cells were incubated for
72 hours with compound 1  in concentrations ranging
from 10 nM to 20 mM after seeding. The compound
appears to have no effect at the concentration correspond-
ing to U87MG and DBTRG-05-MG IG50. However, the
compound becomes toxic to normal human astrocytes
when its concentration exceeds 10 mM (Figure 7a). From
these results we can conclude that compound 1  could
have an acceptable therapeutic window because in the
concentration range [10 nM ®  10 mM], the compound
shows a good anti-proliferative effect on the glioma cell-
lines without any interference with the normal human
astrocytes behavior.
As proof that KIF11 inhibitors don't affect transport
kinesin and that as such are specific compounds that
block only the spindle formation and not the axonal
transport, we tested compound 1 in rat pure cortical neu-
rons, which are non dividing cells. Typically, primary rat
cortical neurons (after 12 days of maturation) were plated
at a density of 300000 cells/well in 24 well plates. 24
hours after plating, cells were incubated for 72 hours with
compound 1 in concentrations ranging from 10 nM to 20
mM. The compound appeared to have the same behavior
seen with normal astrocytes: the compound was toxic at
concentrations exceeding 10 mM and no effect could be
observed at the concentration corresponding to U87MG
and DBTRG-05-MG IG50 (Figure 7b).
Both the human astrocytes and the rat cortical neuron
results were confirmed by One Way Anova analysis
(Tuckey's multiple comparison tests). In these experi-
ments, starting from 500 nM, the overall viability of
U87MG was significantly different from that of rat pure
cortical neurons and normal human astrocytes (P value <
0.01), while DBTRG-05-MG viability started to be signifi-
cantly different at 1 mM (P value < 0.01). At 20 mM there
were no differences between glioma cell-lines, normal
human astrocytes and rat pure cortical neurons (Figure
7c), probably due to the toxicity of the compound. From
these results we could conclude that compound 1 affects
only GBM cell lines proliferation and not normal astro-
cytes proliferation, its therapeutic window appears suita-
ble for future clinical applications. Furthermore, the
compound affects only the KIF11 function and not the
transport kinesins.
Discussion
In the current study, mitotic kinesin KIF11, which is
required for the separation of duplicated centrosomes and
for the spindle formation [17], was deemed to be a prom-
ising target for glioblastoma treatment. The expression
profile of KIF11 mRNA in glioblastoma cells versus nor-
mal astrocytes was first assessed. KIF11 mRNA expression
is reported to be elevated in tumor samples compared
with adjacent normal tissue in tumors derived from
breast, colon, lung, ovary, rectum and uterus [18]. We
confirmed this trend in GBM cell-lines (U87MG and
DBTRG-05-MG) versus normal human astrocytes (data
not shown).
Forward chemical genetics were applied to investigate the
phenotypic effect of KIF11 inhibitors on GBM prolifera-
tion, apoptosis and cell cycle. This implied the selection
BBB-permeating compounds known to specifically
inhibit the target without affecting normal brain function.
Effect of the Ispinesib analog 1 on induction of apoptosis in  U87MG Figure 6
Effect of the Ispinesib analog 1 on induction of apop-
tosis in U87MG. The cells after cell adhesion were incu-
bated for 24 hours with compound 1 in a concentration 
range from 10 nM to 30 mM. The level of caspase 3 activation 
has been used as an indicator of apoptosis induction. The 
caspase 3 activation level was assessed after 24 hours of cell 
treatment with the compound at increasing concentrations 
(from 10 nM to 30 mM). The Ispinesib analog 1 induced a 2-
fold increase of caspase 3 levels, suggesting that this com-
pound was a strong inducer of apoptosis in GBM cells.BMC Cancer 2009, 9:196 http://www.biomedcentral.com/1471-2407/9/196
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To perform this study, we had access to a panel of existing
preclinical efficacious KIF11 inhibitors. Monastrol (3),
the first reported small molecule inhibitor, the quina-
zolinone derivative inhibitor from Cytokinetics SB-
715992 and MKI-833, the Merck reported inhibitor (2)
were demonstrated to be potent inhibitors of cell prolifer-
ation in several human tumor cell-lines (lung NCI-H460,
A549; breast MDA-MB-231, MCF-7; colon HT29; ovarian
SKOV-3, OVCAR-3; leukaemia HL-60, K-562, CNS SF-
268; renal A498; osteosarcoma U2-OS; cervical HeLa)
[14]. Ispinesib is being advanced to Phase II clinical trials
as a general cancer therapeutic agent for cancers such as
breast, ovarian and others. Moreover Monastrol (3) and
other monastrol analogues are reported to be specific
inhibitors of human GBM cells inducing growth inhibi-
tion and affecting spindle formation [13] without affect-
ing the other kinesin-driven motor functions. Moreover,
we selected a small set of Merck compound analogues
Assessment of the therapeutic window of compound 1 on Human normal astrocytes and on rat cortical neurons vs U87MG  and DBTRG-05-MG Figure 7
Assessment of the therapeutic window of compound 1 on Human normal astrocytes and on rat cortical neu-
rons vs U87MG and DBTRG-05-MG. The cells were treated for three days with increasing concentrations of the com-
pound 1. Cell viability was assessed using MTT. From the overlay of the curves (panel a) we assessed the therapeutic window 
of compound 1 by comparing cell viability of increasing concentrations of the compound (from 10 nM to 20 mM) on human 
normal astrocytes (green curve) versus GBM cell lines U87MG (black curve) and DBTRG-05-MG (red curve). The neurotoxic-
ity was assessed testing compound 1 on rat cortical neurons proliferation (panel b). In panel c the same experiment was 
reported as bar graph to underline the statistical differences at each concentration point. U87MG (gray bars) and DBTRG-05-
MG (light gray bars) cells started to be statistically different from 500 nM and 1 mM respectively when compared to normal 
human astrocytes (black bars) and rat pure cortical neurons (white bars) where compound 1 was un-effective.
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whose smaller size meant they had greater probability of
being brain penetrant. Since reaching the tumor in the
brain was considered a critical criterion, only those com-
pounds predicted to be BBB permeant were further inves-
tigated. The ability to pass the BBB is dependent on
multiple factors, including lipophilicity, ionization pro-
file, molecular size, polar surface area and molecular flex-
ibility [19,20]. Relatively lipophilic drugs can cross the
BBB by passive diffusion while polar molecules normally
do not cross it unless they are substrates of specific active
transport systems. There are several computational in silico
tools that help chemists and biologists understand the
complex physico-chemical features of compounds, and
hence to predict the BBB properties of a molecule. In this
study, two computational-statistical suites have been used
for that purpose: VolSurf (VOLSURF, version 4.0; availa-
ble from Molecular Discovery Ltd.: London, U.K. http://
www.moldiscovery.com) and Cerius2 (Cerius2 version
4.11, available from Accelrys Inc. http://www.accel
rys.com). These data provided a robust base for assigning
the probability of compounds for crossing the BBB based
on their physico-chemical profile. Only compounds 2, 3,
4, 5 and 6, having passed the BBB selection filter, were fur-
ther analyzed for their capacity to affect cell proliferation,
to block the cell cycle and to induce apoptosis. We
showed that the Ispinesib analogue compound 1 (Figures
2 and 3) has a higher anti-proliferative activity against
human GBM cell lines when compared to Monastrol (3)
and to the Merk fragments (4, 5 and 6). The effect of com-
pound  1  on GBM cell-lines was also reflected by an
increase of caspase 3 activity and by cell cycle block in G2/
M phase.
In the neurotoxicity experiments carried against normal
human astrocytes and rat cortical neurons, compound 1
revealed to be characterized by a relatively broad thera-
peutic window. This could at least partially be attributed
to compound 1 selectivity for KIF11 over transport kines-
ins.
Monastrol (3), Ispinesib MKI-833 (2) and the majority of
KIF11 inhibitors have been shown to have the same
mechanism of action; they allosterically alter the ability of
KIF11 to bind to microtubules and inhibit their move-
ment by preventing the release of ADP without preventing
the release of the KIF11-ADP complex from the microtu-
bule [21]. This non-ATP binding, allosteric site, which is
formed by helices a2 and a3 and Loop 5 appears to be
specific for KIF11. However, several studies have shown
that loop 5 mutations may induce resistance problems
such as those demonstrated in colorectal cancer cells [22].
Should such mutability be identified in GBM patients as
well, a need for KIF11 inhibitors that bind away from loop
5 may arise. The design of such novel KIF11 inhibitors,
should take into account the recent evidence [23] that
ATP-competitive compounds can/should not interfere
with microtubule dynamics.
Overall, although specific KIF11 inhibitors are of great
value to GBM, mechanism-based toxicity of kinesin inhib-
itors in general may limit the development of specific
mitosis inhibitors.
Conclusion
In this study we combined chemical, in silico ADME and
PK properties and biological approaches to analyze the
effect of a pannel of mitotic kinesin KIF11 inhibitors on
Glioblastoma cell lines. Following an in silico selection for
BBB penetration, KIF11 inhibitors were analysed for their
effect on cell proliferation, cell-cycle and apoptosis induc-
tion. The Ispinesib analog 1, which resulted able to not
only affect cell proliferation, but also block cell cycle and
induce apoptosis, was tested in normal human astrocytes
and in rat pure cortical neurons to evaluate its therapeutic
window and neurotoxicity. Although specific KIF11
inhibitors demonstrating a broad therapeutic window
could be of great value for the treatment of GBM, the
design of these compounds is hampered by high homol-
ogy between motor and mitotic kinesins.
Methods
Physico-chemical descriptors
VolSurf is molecular modeling software that generates 2D
molecular descriptors from 3D molecular interaction field
(MIF) on GRID maps [24]. VolSurf compresses the infor-
mation contained in 3D maps calculated by GRID into a
predefined set of 2D numerical descriptors that can be
interpreted in terms of structure. The GRID force field uses
a potential based on the total energy of interaction [the
sum of Lennard-Jones (ELJ), H-bonding, electrostatic
(EHB) and hydrophobic terms (EQ) added to the Entropic
term (S)] between a target molecule and a probe.
VolSurf was used to calculate the principal molecular
physico-chemical properties, translated into descriptors
within statistical analyses and it is specifically designed for
the optimization of in silico ADME and pharmacokinetic
properties for pharmaceutically relevant compounds [24].
The cross-validation in this study was performed with
Cerius2, a software providing tools for drug design similar
to VolSurf, but based on different algorithms for statistical
analysis, calculation of descriptors and prediction onto
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global models. In this case, the Cerius2 global BBB model
was used for cross-validating the predictions in VolSurf.
Compounds synthesis
The Ispinesib analogue compound 1 (Figure 8) was syn-
thesized following slight modifications from the reported
literature (WO200198278 A1). Monastrol, compound 3,
is commercially available from Sigma-Aldrich. A small
subset of compounds was also selected from our com-
pound collection which could be considered as 'fragments
'of Merck compound, compound 2, and further described
as 'Merck fragments'. These compounds are 4, 5, and 6 (as
shown in Figure 8). Merck compound, compound 2, was
obtained by Ferrara University with a few modifications
from the literature ([25] and WO2004087050).
Glioma cells
GBM cell lines examined, U87MG (derived from a de
novo GBM) and DBTRG-05-MG (derived from recurrent
GBM), were both obtained from Interlab Cell Line Collec-
tion (Genova, Italy). U87MG and DBTRG were cultured
in RPMI containing 10% heat inactivated fetal bovine
serum (Fbs), 2 mM Glutamax, 100 units/ml Penicillin
and 100 mg/ml Streptomycin. For this study were also
used primary cultures of rat pure cortical neurons
obtained from embryonic day (E) 12 rat embryos accord-
ing to a well established method that allow the growth of
a >99% pure neuronal population [26]. Normal human
astrocytes were obtained from Lonza. The primary cul-
tures of rat pure cortical neurons were grown in neuroba-
sal medium supplemented with B27 in 24-well plates. All
cell types were maintained in water saturated atmosphere
(5% CO2) at 37°C.
Proliferation assay
Cell proliferation was measured using MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
SIGMA] -based assay. U87MG and DBTRG-05-MG were
Chemical structures of the compounds used Figure 8
Chemical structures of the compounds used. the analogue of Ispinesib 1, analogue of Merck compounds 2, Monastrol 3 
and 4, 5, 6 which could be considered as fragments of compound 2.BMC Cancer 2009, 9:196 http://www.biomedcentral.com/1471-2407/9/196
Page 13 of 14
(page number not for citation purposes)
plated at a density of 10000 and 20000 cells per well,
respectively, normal human astrocyte and rat cortical neu-
rons at a density of 30000 cells per well in 24-well tissue
culture plate in a total volume of 500 mL medium per well.
After cell adhesion the medium was replaced with
medium containing different concentrations range of
compound 1, from 10 nM to 20 mM, or compounds 3, 4,
5 and 6, from 10 nM to 200 mM. Following three days of
incubation, the medium was replaced by 250 mL fresh
medium without Fbs and 25 mL of MTT solution 5 mg/ml
were added to each well. After an incubation time of 4
hours at 37°C, the formazan crystals formed by the meta-
bolically active cells were solubilized by addition of 250
ml solution constituted by isopropanol, Triton X-100 and
HCl. The 24 well plates were shaken for 10 min on a
microplate shaker and absorbance at 570 nm was meas-
ured using a plate reader [Victor III, Perkin Elmer].3 Back-
ground absorbance at 690 nm was subtracted before data
analysis. The anti-proliferative activity was calculated as
percentage of remaining viable cells after treatment versus
control untreated cells. Each experiment was performed at
least in duplicate in three different experiments. Data
analysis was performed using Excell Fit software.
Cell-cycle flow cytometry
Cell cycle distribution after compound treatment was
determined by measuring the amount of cellular DNA
using propidium iodide staining. U87MG and DBTRG-
05-MG cells were plated at a density of 1000000 in a T75
flask; the day after cells were synchronized in serum free
conditions for 24 h and then incubated for 24 hours with
a fixed concentration (1 mM) of compound 1 or Nocoda-
zole. Following incubation, the cells were harvested and
fixed with cold ethanol, washed with PBS, treated with 10
mg/ml RNAse for 15 minutes, and incubated with 50 mg/
ml propidium iodide for 15 minutes. DNA content in dif-
ferent phases of cell cycle was determined using flow
cytometry (FACScalibur, BD Biosciences Immunocytome-
try System) measuring propidium iodide emission at 580
nm. Cell cycle distribution was analyzed using BD Cel-
lQuest™ Pro software (BD Biosciences Immunocytometry
System).
Apoptosis Assay
The effect of the compound 1 on apoptosis was tested
using a time resolved fluorescence technology based on
the TruPoint™ Caspase-3 Kit96 (PerkinElmer, USA). This
kit is based on the measurement of increased caspase 3/7
activity. When active, caspase 3 cleaves the substrate Z-
DEVD and forms aminoluciferin, which is in turn a sub-
strate for luciferase. The cells were plated at a density of
10000 cells per well in white ViewPlate™-96 wells (Perk-
inElmer, USA) and after cell adhesion they were incubated
for 24 hours with compound 1 in a concentration range
from 10 nM to 30 mM. Subsequently the cells were washed
and total cellular protein extract was prepared. Specific
substrate and detection buffer were added and the lumi-
nescence was measured. (Victor III, PerkinElmer). Induc-
tion of apoptosis was evaluated as percentage of caspase 3
activation in treated versus control (untreated) cells. Each
experiment was performed in triplicate in three different
experiments.
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